Based on histological features and the developmental stage of lymphocytes, non-Hodgkin's lymphoma (NHL) is defined as B-cell and T-cell neoplasms. 1 The most common types of NHL are diffuse large B-cell lymphoma (DLBCL), which accounts for 30-40% of lymphomas in developed countries, and follicular lymphoma (FL), which accounts for approximately 20-30% of lymphomas. 2 The incidence of NHL has increased nearly two-fold over the past few decades, with AIDS-related lymphoma accounting for some of this expansion and environmental factors probably playing a role. 3 NHL accounts for approximately 8-10% of all childhood malignancies. 4 The prognosis of both localised and advanced childhood and adolescent NHL has improved considerably over the past 30 years. 5, 6 Follicular Lymphoma . 12 HDT significantly improved event-free survival from relapse and survival after relapse (SAR). Interestingly, patients in relapse fared best when they received rituximab/chemotherapy plus HDT compared with immuno-
Based on histological features and the developmental stage of lymphocytes, non-Hodgkin's lymphoma (NHL) is defined as B-cell and T-cell neoplasms. 1 The most common types of NHL are diffuse large B-cell lymphoma (DLBCL), which accounts for 30-40% of lymphomas in developed countries, and follicular lymphoma (FL), which accounts for approximately 20-30% of lymphomas. 2 The incidence of NHL has increased nearly two-fold over the past few decades, with AIDS-related lymphoma accounting for some of this expansion and environmental factors probably playing a role. 3 NHL accounts for approximately 8-10% of all childhood malignancies. 4 The prognosis of both localised and advanced childhood and adolescent NHL has improved considerably over the past 30 years. 5, 6 Follicular Lymphoma Follicular lymphomas represent the second most frequent subtype of nodal lymphoid malignancies in Western Europe. The Non-Hodgkin's Lymphoma Classification Project, which examined a cohort of 1,403 lymphoma biopsies from previously untreated NHL patients from nine sites worldwide, diagnosed FL in 22% of cases. 7 Furthermore, in recent decades the annual incidence of FL has increased rapidly, rising from two to three per 100,000 persons during the 1950s to five per seven per 100,000 persons. 8 The World Health Organization (WHO) classification of NHL separates follicular lymphoma into three grades based on the proportion of centroblasts in neoplastic follicles. 9 FL grade 1 is diagnosed when up to five centroblasts per high-power (microscope) field (hpf) are counted, while FL grade 2 is diagnosed when six to 15 centroblasts per hpf are counted. FL grade 3 is characterised by more than 15 centroblasts per hpf, and it is subdivided into grade 3a when centrocytes are present and 3b when solid sheets of centroblasts are observed. FL grades 1, 2 and 3a are considered to be indolent, whereas 3b is considered to be an aggressive variant of FL. FL grade 3b has displayed similar histological features to the DLBCL component. In the presence of the DLBCL component, patients with FL grade 3b were less likely to harbour the t(14;18) translocation, which is quite common in the other grades, but were more likely to display aberrations in chromosome band 3q27 and overexpress the tumour suppressor gene p53. 10 The current European Society for Medical Oncology (ESMO) guidelines recommend radiotherapy as first-line therapy in patients with limited stage I-II disease, and advise that systemic therapy should be considered in patients with large tumour burden. 11 In patients with advanced stage III and IV disease, no curative therapy is yet chemotherapy or HDT alone. Patients treated with a rituximabcontaining salvage regimen followed by HDT had five-year SAR of more than 90%. 12 These data suggest that HDT after rituximab/ chemotherapy may add additional clinical benefit, a question which will be addressed for intermediate-/high-risk FL-treatment-naïve patients by an international study (Ri-CHOP study) co-ordinated by the German Low-grade Lymphoma Study Group (GLSG): in this trial patients in need of therapy will be randomised to either R-CHOP followed by rituximab maintenance or R-CHOP followed by consolidating HDT and subsequent rituximab maintenance. Radioimmunotherapy (RIT) should also be considered in the consolidation setting in relapsed disease, particularly in antibody-refractory patients and in widespread disease following multiple prior therapies. 11 The Follicular Lymphoma International Prognostic Index (FLIPI) 13 was developed to predict the prognosis of patients with FL. Based on five easily obtained clinical and laboratory parameters such as age, Ann Arbor stage, number of nodal areas, LDH and haemoglobin levels, the FLIPI discriminates between three major subgroups of patients with FL with regard to overall survival, carrying a low-(none to one risk factors), intermediate-(two risk factors) or high-risk (three to five risk factors) factor. 14 A recent analysis evaluated FLIPI's predictive value in rituximab-treated advanced FL patients and found that FLIPI identified high-risk patients with advanced-stage FL after first-line treatment with rituximab chemotherapy. 13 There are ongoing efforts to develop a novel prognostic score validated after rituximab chemotherapy. 15 
Antibody Therapy in Follicular Lymphoma
Rituximab is a chimaeric immunoglobulin G (IgG) kappa monoclonal antibody that recognises the CD20 antigen expressed on normal B cells and most malignant B-cell lymphomas. 15 The addition of rituximab to the armamentarium of agents for the treatment of NHL has greatly improved management of the disease. Since its approval for clinical use in 1997, rituximab (either as part of induction treatment or as maintenance therapy) [17] [18] [19] [20] [21] [22] [23] has improved response rates and prolonged OS in patients with follicular NHL and DLBCL. 21 Ongoing research is being conducted to define the timing (schedule) and administration necessary for optimum treatment of hard-to-cure lymphomas.
However, nearly every third patient in the first-line setting 25 and about half of patients at relapse 19 do not respond to rituximab single-agent treatment, and virtually all patients suffer from recurrent disease or progress at some time after rituximab treatment, revealing the critical need to improve and enhance the efficacy of monoclonal antibody activity. RIT is a new modality of targeted therapy in which conjugated radioisotopes to anti-CD20 antibodies are delivered to tumour targets.
The Rituximab Era
Evidence from several clinical trials lead to the same conclusion: rituximab plus chemotherapy is more efficient than chemotherapy alone for improving remission rates, duration of response and OS in FL as first-line treatment. Hiddemann et al. randomised 428 patients with untreated, advanced-stage FL for chemotherapy with CHOP alone or CHOP combined with rituximab (R-CHOP). 26 The R-CHOP combination reduced the relative risk of treatment failure by 60%, and significantly prolonged the time to treatment failure.
The addition of rituximab to CVP increased both complete and overall response rates (ORR), and prolonged the median time to disease progression (34 months versus 15 months) compared with CVP alone (p<0.0001). The four-year disease-free survival (DFS) rate for patients with a complete response/complete response unconfirmed (CR/CRu) was 54% with R-CVP versus 17% with CVP (p=0.0001). In addition, the four-year estimated OS rate was 83% with R-CVP versus 77% with CVP alone. 27 In patients with previously untreated advanced FL, rituximab plus mitoxantrone, chlorambucil and prednisolone chemotherapy (MCP) demonstrated an ORR of 92% and a CR rate of 50% versus 75% ORR and 25% CR for MCP alone (p<0.0001). At 47 months median follow-up, the median event-free survival (EFS) time was significantly prolonged with R-MCP compared with MCP alone: EFS not reached versus 26 months, respectively (p<.0001). Similarly, PFS was significantly prolonged to 28.8 months with R-MCP, whereas it was not reached with MCP (p<0001). R-MCP also yielded a significantly improved four-year overall survival rate of 87% compared with the 74% achieved with MCP alone (p=0.0096). 28 The final analysis of the GELA-GOELAMS FL2000 Study with a 
Consolidation Therapy for Follicular Lymphoma
The aim of consolidation therapy is to further improve the quality of response, preferably with the eradication of minimal residual disease (MRD) after successful cytoreduction by chemotherapy. Myeloablative therapy before ASCT and RIT are two potential consolidation strategies that have been investigated in the clinical setting as both first-and second-line therapy. Consolidation therapy with rituximab as a single agent delivered short-term has not been established for either FL or aggressive lymphoma. As opposed to myelablative therapy followed by ASCT or RIT, which both take around 14 days, rituximab maintenance treatment continues over a period of two years.
Radioimmunotherapy
RIT is a treatment modality that combines the specificity of monoclonal 
Radioimmunotherapy as Consolidation Therapy
Studies evaluating RIT as consolidation therapy have shown promising data. A phase II trial of CHOP followed by tositumomab/ 131 I-tositumomab for previously untreated FL in 90 eligible patients with previously untreated advanced-stage FL reported an OR of 91%, with a 69% CR rate. The estimated five-year OS rate was 87%, and the PFS rate was 67%.
These data were superior to corresponding figures for patients treated on previous Southwest Oncology Group protocols with CHOP alone. 36 Interestingly, 21% of patients with FLIPI high-risk features had worse OS than lower-risk patients (p=0.05), although no differences were reported in PFS between FLIPI-stratified groups.
Another phase II study evaluated the efficacy of abbreviated chemotherapy with fludarabine followed six to eight weeks later with tositumomab/ 131 I-tositumomab. After the fludarabine course, 89% of 35 patients and 9% of 31 patients achieved CR. Following 131 I-tositumomab consolidation therapy, all 35 patients responded and 86% achieved CR. 37 A preliminary study evaluated 90 Y-ibritumomab tiuxetan following CHOP-rituximab. After CHOP-rituximab, the CR rate was 28%. After RIT, the CR rate was 67%. 38 
Follicular Lymphoma in the Future
One issue that will become the centre of attention in the future is the treatment of elderly and medically non-fit cancer patients. Due to the general ageing of the population in the western world, FL will become the burden of the elderly. The number of lymphoma patients aged between 65 and 90 years will increase and their treatment will present a serious challenge. Non-lymphoma-related co-morbidities such as heart and renal disease that are common in elderly patients will render high-dose intensive chemotherapy not feasible for their treatment. These patients urgently need a new concept of treatment, and monoclonal antibody therapy is an attractive alternative for these difficult-to-treat patients. I Hypersensitivity to ibritumomab tiuxetan, to yttrium chloride, to rituximab, to other murine proteins or to any of the excipients.
Pregnancy and lactation. Warnings and precautions:
Radiopharmaceutical agents should only be used by qualified personnel with the appropriate government authorisation for the use and manipulation of radionuclides. Severe and prolonged cytopenia, generally reversible. The risk of hematologic toxicity may be increased when Zevalin® is administered shortly (<4 months) after fludarabine containing regimens. Not to be administered to: patients likely to develop hematological toxicity signs; patients in whom more than 25% of the bone marrow has been infiltrated by lymphoma cells; patients who have received external beam radiation involving more than 25% of active bone marrow; patients with platelet counts <100,000/mm3 (monotherapy) or <150,000/mm 3 (consolidation); patients with neutrophil counts <1,500/mm3; patients with prior bone marrow transplant or stem cell support; children and adolescents. Growth factors not to be used 2 weeks before and after Zevalin®. Very common: thrombocytopenia, leukocytopenia, neutropenia, anemia, nausea, asthenia, pyrexia, rigors. Common: infection ‡ , sepsis ‡ , pneumonia ‡ , urinary tract infection, oral moniliasis, tumor pain, myelodysplastic syndrome/acute leukemia ‡ , febrile neutropenia, pancytopenia ‡ , lymphocytopenia, hypersensitivity reaction, anorexia, anxiety, insomnia, dizziness, headache, hemorrhage while thrombocytopenic ‡ , cough, rhinitis, vomiting, abdominal pain, diarrhea, dyspepsia, throat irritation, constipation, rash, pruritus, arthalgia, myalgia, back pain, neck pain, pain, flulike symptoms, malaise, peripheral edema, sweating increased. Uncommon: tachycardia. Rare: meningioma, intracranial hemorrhage while thrombocytopenic ‡ . ‡ fatal outcome has been observed in clinical trials or in postmarketing experience. In the study with 204 patients following first-line remission induction, infections were observed more frequently than as described above (very common). In addition, the following adverse drug reactions were observed in this study: very common: fatigue, petechia. Common: hypertension, hypotension, amenorrhea. Post-marketing experience: mucocutaneous reaction, including Stevens Johnson Syndrome with fatal outcome, has been rarely reported in post-marketing experience. Isolated reports of extravasation with subsequent infusion site reaction, like dermatitis, desquamation and site ulcer have been received. Isolated reports have been received showing that Zevalin®-associated radiation might cause damage to lymphoma-surrounding tissue and complications due to lymphoma swelling. Because the Zevalin® therapeutic regimen includes the use of rituximab, see also prescribing information of rituximab.
Date of revision of the text: April 2008.
For current prescribing information refer to the package insert and/or contact your local Bayer Schering Pharma organization. Bayer Schering Pharma AG, 13342 Berlin, Germany. 
